Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients

@article{Kerbusch2001PopulationPO,
  title={Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients},
  author={Thomas Kerbusch and John W. G van Putten and Harry J. M. Groen and Alwin D. R. Huitema and Ron A. A. Math{\^o}t and Jos H. Beijnen},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2001},
  volume={48},
  pages={53-61}
}
The aim of this study was to develop a population pharmacokinetic model that could describe the pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide, and calculate their plasma exposure and urinary excretion. A group of 14 patients with small-cell lung cancer received a 1-h intravenous infusion of 2.0 or 3.0 g/m2 ifosfamide over 1 or 2 days in combination with 175 mg/m2 paclitaxel and carboplatin at AUC 6. The concentration-time profiles of ifosfamide were… CONTINUE READING